Beijing
China
Beijing Cancer Hospital
lung adenocarcinoma, micropapillary, stage I, recurrence-free survival, adjuvant chemotherapy
lung cancer, immune checkpoint inhibitors, rechallenge, efficacy, safety, nomogram